Seeking Alpha

Teva Pharmaceuticals (TEVA +0.9%) agrees to delay the introduction of generic versions of two...

Teva Pharmaceuticals (TEVA +0.9%) agrees to delay the introduction of generic versions of two Gilead (GILD -0.9%) HIV drugs, Truvada and Viread, until June 1 or until a judge rules on the patent fight between the two companies. GILD sued TEVA in 2008 and again in 2010, claiming its FDA applications to make HIV drugs infringed four of its patents. The complaints also listed the HIV drug Atripla, which wasn’t cited in today’s filing.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|